Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30022213HIVENSG00000198793.14protein_codingMTORYesNo2475P42345
TVIS30022214HIVENSG00000198793.14protein_codingMTORYesNo2475P42345
TVIS30022215HIVENSG00000198793.14protein_codingMTORYesNo2475P42345
TVIS30022216HIVENSG00000198793.14protein_codingMTORYesNo2475P42345
TVIS30022217HIVENSG00000198793.14protein_codingMTORYesNo2475P42345
TVIS30022218HIVENSG00000198793.14protein_codingMTORYesNo2475P42345
TVIS30022219HIVENSG00000198793.14protein_codingMTORYesNo2475P42345
TVIS30022220HIVENSG00000198793.14protein_codingMTORYesNo2475P42345
TVIS30022221HIVENSG00000198793.14protein_codingMTORYesNo2475P42345
TVIS30022222HIVENSG00000198793.14protein_codingMTORYesNo2475P42345
TCGA Plot Options
Drug Information
GeneMTOR
DrugBank IDDB12843
Drug NameOleandrin
Target IDBE0002386
UniProt IDP42345
Regulation Typedownregulator
PubMed IDs32452588
CitationsRoth MT, Cardin DB, Borazanci EH, Steinbach M, Picozzi VJ, Rosemury A, Wadlow RC, Newman RA, Berlin J: A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma. Oncologist. 2020 Oct;25(10):e1446-e1450. doi: 10.1634/theoncologist.2020-0440. Epub 2020 Jul 2.
GroupsExperimental; Investigational
Direct ClassificationCardenolide glycosides and derivatives
SMILESCO[C@H]1C[C@H](O[C@H]2CC[C@@]3(C)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H]([C@H](C[C@]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[C@@H](C)[C@@H]1O
Pathways
PharmGKB
ChEMBLCHEMBL1075789